Evidence map›Paper›PMID 30564209›Full record

ArticleFrontiers in microbiology2018

Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals.

Mingxiao Chen, Fuxiang Zheng, Guosheng Yuan, Xiaobing Duan, Liang Rong, Junwei Liu, Shengjun Feng, Ziting Wang, Min Wang, Yetong Feng and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Mingxiao ChenInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Fuxiang ZhengInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Guosheng YuanDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaobing DuanInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Liang RongInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Junwei LiuDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shengjun FengInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Ziting WangInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Min WangGuangzhou Blood Center, Guangzhou, China.
Yetong FengInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Qing ZhouInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Jinqian LiInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Kai DengInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Chunna LiProgram of Pathobiology, The Fifth Affiliated Hospital and Zhongshan School of Medicine, Sun Yat-sen University, Guangdong, China.
Jinyu XiaProgram of Pathobiology, The Fifth Affiliated Hospital and Zhongshan School of Medicine, Sun Yat-sen University, Guangdong, China.
Guirong RaoKey Laboratory of Liver Disease, Center of Infectious Diseases, PLA 458 Hospital, Guangzhou, China.
Yuanping ZhouDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yongshui FuGuangzhou Blood Center, Guangzhou, China.
Yi-Ping LiInstitute of Human Virology and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Sun Yat-sen University · CNFifth Affiliated Hospital of Sun Yat-sen University · CNGuangzhou Blood Center · CNNanfang Hospital · CN421 Hospital of PLA · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) is classified into seven major genotypes, and genotype 6 is commonly prevalent in Asia, thus reverse genetic system representing genotype 6 isolates in prevalence is required. Here, we developed an infectious clone for a Chinese HCV 6a isolate (CH6a) using a novel strategy. We determined CH6a consensus sequence from patient serum and assembled a CH6a full-length (CH6aFL) cDNA using overlapped PCR product-derived clones that shared the highest homology with the consensus. CH6aFL was non-infectious in hepatoma Huh7.5 cells. Next, we constructed recombinants containing Core-NS5A or 5'UTR-NS5A from CH6a and the remaining sequences from JFH1 (genotype 2a), and both were engineered with 7 mutations identified previously. However, they replicated inefficiently without virus spread in Huh7.5 cells. Addition of adaptive mutations from CH6a Core-NS2 recombinant, with JFH1 5'UTR and NS3-3'UTR, enhanced the viability of Core-NS5A recombinant and acquired replication-enhancing mutations. Combination of 22 mutations in CH6a recombinant with JFH1 5'UTR and 3'UTR (CH6aORF) enabled virus replication and recovered additional four mutations. Adding these four mutations, we generated two efficient recombinants containing 26 mutations (26m), CH6aORF_26m and CH6aFL_26m (designated "CH6acc"), releasing HCV of 10

Indexed as

adaptive mutationcell culture systemconsensus sequencedirect-acting antiviral agentsgenotypehepatitis C virus

Identifiers

PMID30564209
PMCPMC6288186
OpenAlexW2902583913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.